Day 2 – 22 September 2021
Interactive Poster session 3
Clinical significance of intensity of glomerular galactose-deficient IgA1 deposition in IgA nephropathy
Evaluation of pharmacological mechanism of hydroxychloroquine in murine IgA nephropathy
Co-culture with plasmacytoid DC and B cell enhance IgA production through TLR9/APRIL signaling in murine model of IgA nephropathy
Galactose-deficient IgA1-containing immune complexes deposit in mesangium mediated by endothelial cell injuries
The benefit of combining corticosteroid therapy with tonsillectomy in pathologically advanced IgA nephropathy
|Industry Symposium 3|
|10:20–11:20||Industry Symposium 4|
Plenary Session 5
Formulation of the 2021 Guideline and what to expect in the future
Key updates in the 2021 IgAN & IgAV Guideline
Key unmet needs identified following the KDIGO guideline review
Free Communications 2
eGFR slope at 1 year may independently predict clinical benefit in patients with IgA nephropathy
Interim Results of a Phase 1/2 Trial to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of BION-1301 in Patients with IgA Nephropathy
Pathogenetic mechanisms involved in hematuria bouts after respiratory tract infections in IgA nephropathy
Serum APRIL as a biomarker in South-Asian prospective longitudinal observational IgA nephropathy cohort (GRACE-IgANI)
IgA-Complement immune complexes: A novel mechanism for the delivery of complement proteins to the glomerulus in IgA nephropathy
Panel Discussion 2
Panel members: Daniel Cattran (Canada), Rosanna Coppo (Italy), Bruce Julian (United States), Zhi Hong Liu (China)
|14:50–15:20||Industry Symposium 6b|
Plenary Session 6
Targeting pathogenic IgA production
Modulating non-immune pathways-how might this help?
Inhibiting complement activation in IgAN
Plenary Session 7
How do we improve the International IgAN Prediction Tool?
What biomarkers are on the horizon that may help risk stratify patients with IgAN?
How can we use big data from CKD to improve prognostication in IgAN?
Plenary Session 8
How has COVID-19 changed our views on delivering clinical trials?
The Importance of Patient Reported Outcomes in IgAN Clinical Trial Design
Novel clinical trial designs and what they could deliver in IgAN
|18:05–19:05||Industry Symposium 4|
|19:10–20:10||Industry Symposium 3|
Interactive Poster session 4
An Artificial Neural Network (ANN) tool to predict ESKD in immunoglobulin a nephropathy (IgAN). Performance analysis
A New Epigenetically-Driven Mechanism Regulating the IL-6 Levels in IgA Nephropathy
Association of Microhematuria with Outcomes in Adult Patients with IgA Nephropathy
TRF-budesonide (Nefecon) positively impacts serum and urinary biomarkers involved in interstitial fibrosis in patients with IgAN: analysis from the Phase 2 NEFIGAN trial
Randomized clinical study to evaluate the effect of personalized therapy on patients with immunoglobulin a nephropathy (IgAN)
Complement Factor H and THBD rare variants are overrepresented in a French IgA Nephropathy cohort.
All times in the symposium programme are in Central European Summer Time – CEST (UTC + 2).